T-DM1 was not superior to paclitaxel analogs in patients previously treated for HER2-positive advanced GC, but with a higher incidence of grade 3 or higher pulmonary toxicity, thrombocytopenia, and bleeding. Here, ERBB2 is linked to gastric cancer.